Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid
Tools
Sach, Tracey (2018) Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid. British Journal of Dermatology, 178 (2). pp. 320-321. ISSN 0007-0963
Full text not available from this repository. (Request a copy)Item Type: | Article |
---|---|
Uncontrolled Keywords: | cost-benefit analysis,doxycycline,humans,pemphigoid, bullous,prednisolone,quality-adjusted life years |
Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
Depositing User: | LivePure Connector |
Date Deposited: | 16 Jul 2020 23:47 |
Last Modified: | 24 Sep 2020 00:02 |
URI: | https://ueaeprints.uea.ac.uk/id/eprint/76154 |
DOI: | 10.1111/bjd.16226 |
Actions (login required)
![]() |
View Item |